Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
Identifieur interne : 001587 ( Ncbi/Curation ); précédent : 001586; suivant : 001588Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
Auteurs : Anna De Lang [Pays-Bas] ; Albert D M E. Osterhaus ; Bart L. HaagmansSource :
- Virology [ 0042-6822 ] ; 2006.
Descripteurs français
- KwdFr :
- Animaux, Antiviraux (pharmacologie), Cellules Vero (), Cellules Vero (métabolisme), Facteurs temps, Interféron gamma (pharmacologie), Interleukine-4 (pharmacologie), Relation dose-effet des médicaments, Récepteurs viraux (), Récepteurs viraux (métabolisme), Régulation négative, Réplication virale (), Syndrome respiratoire aigu sévère (virologie), Virus du SRAS (physiologie).
- MESH :
- métabolisme : Cellules Vero, Récepteurs viraux.
- pharmacologie : Antiviraux, Interféron gamma, Interleukine-4.
- physiologie : Virus du SRAS.
- virologie : Syndrome respiratoire aigu sévère.
- Animaux, Cellules Vero, Facteurs temps, Relation dose-effet des médicaments, Récepteurs viraux, Régulation négative, Réplication virale.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Chlorocebus aethiops, Dose-Response Relationship, Drug, Down-Regulation, Interferon-gamma (pharmacology), Interleukin-4 (pharmacology), Receptors, Virus (drug effects), Receptors, Virus (metabolism), SARS Virus (physiology), Severe Acute Respiratory Syndrome (virology), Time Factors, Vero Cells (drug effects), Vero Cells (metabolism), Virus Replication (drug effects).
- MESH :
- chemical , drug effects : Receptors, Virus.
- chemical , metabolism : Receptors, Virus.
- chemical , pharmacology : Antiviral Agents, Interferon-gamma, Interleukin-4.
- drug effects : Vero Cells, Virus Replication.
- metabolism : Vero Cells.
- physiology : SARS Virus.
- virology : Severe Acute Respiratory Syndrome.
- Animals, Chlorocebus aethiops, Dose-Response Relationship, Drug, Down-Regulation, Time Factors.
Abstract
Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment. In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4 acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on cells treated with IL-4, but also on cells exposed to IFN-gamma. Consistent with these observations, IL-4 and IFN-gamma downregulated cell surface expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2 mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-gamma inhibit SARS-CoV replication partly through downregulation of ACE2.
DOI: 10.1016/j.virol.2006.06.011
PubMed: 16860835
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002156
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002156
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002130
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001587
Links to Exploration step
pubmed:16860835Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.</title><author><name sortKey="De Lang, Anna" sort="De Lang, Anna" uniqKey="De Lang A" first="Anna" last="De Lang">Anna De Lang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16860835</idno><idno type="pmid">16860835</idno><idno type="doi">10.1016/j.virol.2006.06.011</idno><idno type="wicri:Area/PubMed/Corpus">002156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002156</idno><idno type="wicri:Area/PubMed/Curation">002156</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002156</idno><idno type="wicri:Area/PubMed/Checkpoint">002130</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002130</idno><idno type="wicri:Area/Ncbi/Merge">001587</idno><idno type="wicri:Area/Ncbi/Curation">001587</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.</title><author><name sortKey="De Lang, Anna" sort="De Lang, Anna" uniqKey="De Lang A" first="Anna" last="De Lang">Anna De Lang</name><affiliation wicri:level="1"><nlm:affiliation>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam, The Netherlands.</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Virology, Erasmus Medical Center, Dr. Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D M E" last="Osterhaus">Albert D M E. Osterhaus</name></author><author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L" last="Haagmans">Bart L. Haagmans</name></author></analytic><series><title level="j">Virology</title><idno type="ISSN">0042-6822</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiviral Agents (pharmacology)</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Down-Regulation</term><term>Interferon-gamma (pharmacology)</term><term>Interleukin-4 (pharmacology)</term><term>Receptors, Virus (drug effects)</term><term>Receptors, Virus (metabolism)</term><term>SARS Virus (physiology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>Time Factors</term><term>Vero Cells (drug effects)</term><term>Vero Cells (metabolism)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiviraux (pharmacologie)</term><term>Cellules Vero ()</term><term>Cellules Vero (métabolisme)</term><term>Facteurs temps</term><term>Interféron gamma (pharmacologie)</term><term>Interleukine-4 (pharmacologie)</term><term>Relation dose-effet des médicaments</term><term>Récepteurs viraux ()</term><term>Récepteurs viraux (métabolisme)</term><term>Régulation négative</term><term>Réplication virale ()</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Virus du SRAS (physiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Virus</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term><term>Interferon-gamma</term><term>Interleukin-4</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Vero Cells</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Vero Cells</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Cellules Vero</term><term>Récepteurs viraux</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term><term>Interféron gamma</term><term>Interleukine-4</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Chlorocebus aethiops</term><term>Dose-Response Relationship, Drug</term><term>Down-Regulation</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cellules Vero</term><term>Facteurs temps</term><term>Relation dose-effet des médicaments</term><term>Récepteurs viraux</term><term>Régulation négative</term><term>Réplication virale</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interferons (IFNs) inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication and might be valuable for SARS treatment. In this study, we demonstrate that treatment of Vero E6 cells with interleukin-4 (IL-4) decreased the susceptibility of these cells to SARS-CoV infection. In contrast to IFNs, IL-4 did not show antiviral activity when administered immediately after SARS-CoV infection, suggesting that IL-4 acts early during the SARS-CoV replication cycle. Indeed, binding of recombinant SARS-CoV spike protein to Vero E6 cells was diminished on cells treated with IL-4, but also on cells exposed to IFN-gamma. Consistent with these observations, IL-4 and IFN-gamma downregulated cell surface expression of angiotensin-converting enzyme 2 (ACE2), the SARS-CoV receptor. Besides diminished ACE2 cell surface expression, ACE2 mRNA levels were also decreased after treatment with these cytokines. These findings suggest that IL-4 and IFN-gamma inhibit SARS-CoV replication partly through downregulation of ACE2.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001587 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001587 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:16860835
|texte= Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:16860835" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |